Related Experiment Video

Updated: Jun 2, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Effects of antisense oligonucleotides targeting k-ras expression in pancreatic-cancer cell-lines

G Carter1, C Gilbert, N Lemoine

  • 1HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,ICRF ONCOL UNIT,MOLEC PATHOL LAB,LONDON W12 0NN,ENGLAND. IMPERIAL CANC RES FUND,VIDEOMICROSCOPY & MICROINJECT LAB,LONDON WC2A 3PX,ENGLAND.

International Journal of Oncology
|May 11, 2011
PubMed

Insights

Antisense oligonucleotides targeting the K-ras oncogene showed dose-dependent antiproliferative effects in pancreatic cancer cells. However, this approach did not reduce K-ras expression, indicating a need for further development in genetic cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The K-ras oncogene is frequently activated in pancreatic cancer, making it a significant therapeutic target.
  • Genetic interventions targeting oncogenes are a promising area of cancer research.

Purpose of the Study:

  • To evaluate the efficacy of K-ras antisense oligonucleotides in human pancreatic cancer cell lines.
  • To determine if K-ras downregulation correlates with antiproliferative effects.

Main Methods:

  • Treatment of human pancreatic cancer cell lines with K-ras antisense oligonucleotides.
  • Assessment of cellular proliferation and K-ras gene expression levels.
  • Investigation of cationic lipid-mediated uptake enhancement.

Main Results:

  • Dose-dependent antiproliferative effects were observed, but not consistently linked to reduced K-ras levels.
  • Altering cellular uptake with cationic lipids did not improve antiproliferative outcomes or K-ras reduction.
  • The study highlights limitations in the current antisense oligonucleotide approach for K-ras inhibition.

Conclusions:

  • K-ras antisense oligonucleotides demonstrate antiproliferative activity but lack specific K-ras downregulation in pancreatic cancer models.
  • Significant advancements are required for antisense oligonucleotides to become effective anti-cancer agents.
  • Alternative strategies are necessary for successful genetic intervention targeting K-ras in human cancers.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...